Highlights Waldencast plc

Stocks

WALD

JE00BPG99318

Other Specialty Retailers

End-of-day quote Nasdaq Other stock markets 15/07/2026			5-day change	1st Jan Change
1.710 ^USD	-4.47%		-1.16%	-9.04%

06-15	Waldencast plc Announces Fda Approval of Obagi Saypha Chiq Injectable Hyaluronic Acid Gel	CI
06-15	Waldencast Says US FDA Approves Obagi Saypha ChIQ Injectable Hyaluronic Acid Gel	MT

Highlights

06-15	Waldencast plc Announces Fda Approval of Obagi Saypha Chiq Injectable Hyaluronic Acid Gel	CI
06-15	Waldencast Says US FDA Approves Obagi Saypha ChIQ Injectable Hyaluronic Acid Gel	MT
05-31	Bridgepoint Europe VII and Bridgepoint Europe VII 2 LP, funds managed by Bridgepoint Advisers Limited, and Gore Range Capital Fund III Llc, a fund managed by Gore Range Capital LLC, entered into a definitive agreement to acquire Obagi Cosmeceuticals LLC, Obagi Netherlands B.V. and Obagi AsiaPac Limited from Obagi Holdings Company Ltd. for $460 million.	CI
05-15	Obagi Medical Shares New Data on Recent Innovations At Music City Symposium for Cosmetic Advances and Laser Education Meeting	CI
05-14	Obagi Medical And Next Health Form Strategic Alliance To Launch The Skin Recharge Station Pop-Up Experience	CI
04-30	Obagi Medical Launches Sun Shield Mineral Uv Barrier Protect Broad Spectrum Spf 40 for Distribution	CI
04-28	Waldencast announces conclusion of SEC investigation	RE
04-28	SEC Drops Investigation Into Waldencast	DJ
03-19	Obagi Medical Part of Waldencast plc and Promd Health Announce Collaboration in the Aloha Program to Advance Clinical Evidence with Obagi Saypha Magiq	CI
03-13	Waldencast plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-25	Obagi Medical and It's a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi®? saypha®? MagIQ	CI
01-27	Obagi Medical and Alpha Aesthetic Partners Announce Their Collaboration in the Aloha Program to Drive Real-World Evidence with Obagi®? Saypha®? MagIQ	CI
11-24	Waldencast plc Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11-24	Waldencast plc Updates Earnings Outlook for 2025	CI
11-24	Waldencast announces Q2 2025 results and provides Q3 2025 trading update	RE
11-16	Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum At the 2025 American Society for Dermatologic Surgery Annual Meeting	CI
10/09/25	Waldencast Says FDA Approves its Obagi Saypha MagIQ Hyaluronic Acid Gel	MT
10/09/25	Waldencast plc Announces FDA Approval of Obagi Saypha MagIQ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand	CI
18/08/25	Waldencast to undertake strategic alternatives review	RE
18/08/25	Waldencast plc Updates Earnings Guidance for the Full Year 2025	CI
23/07/25	Waldencast plc acquired Novaestiq Corp. from Nvq Investors Holding, Llc and CROMA-PHARMA GmbH for $26.9 million.	CI
23/07/25	Waldencast to Acquire Novaestiq, US Rights to Saypha Line of Injectable Hyaluronic Acid Gels	MT
23/07/25	Waldencast acquires Novaestiq Corp. and U.S. rights to leading injectable hyaluronic acid gel line, Saypha, under the Obagi Medical brand	RE
13/05/25	Waldencast Q1 Net Loss Widens, Revenue Falls; Shares Down	MT
22/04/25	Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream	CI